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Serotonin drives the acquisition of 
a profibrotic and anti-inflammatory 
gene profile through the 5-HT7R-
PKA signaling axis
Ángeles Domínguez-Soto1, Alicia Usategui2, Mateo de las Casas-Engel1, Miriam Simón-Fuentes1, 
Concha Nieto1, Víctor D. Cuevas  1, Miguel A. Vega1, José Luis Pablos2 & Ángel L. Corbí1
Peripheral serotonin (5-hydroxytryptamine, 5-HT) regulates cell growth and differentiation in numerous 
cell types through engagement of seven types of cell surface receptors (HTR1–7). Deregulated 5-HT/
HTR levels contribute to pathology in chronic inflammatory diseases, with macrophages being relevant 
targets for the physio-pathological effects of 5-HT. In fact, 5-HT skews human macrophage polarization 
through engagement of 5-HT2BR and 5-HT7R receptors. We now report that 5-HT primes macrophages 
for reduced pro-inflammatory cytokine production and IFN type I-mediated signaling, and promotes 
an anti-inflammatory and pro-fibrotic gene signature in human macrophages. The acquisition of the 
5-HT-dependent gene profile primarily depends on the 5-HT7R receptor and 5-HT7R-initiated PKA-
dependent signaling. In line with the transcriptional results, 5-HT upregulates TGFβ1 production by 
human macrophages in an HTR7- and PKA-dependent manner, whereas the absence of Htr7 in vivo 
results in diminished macrophage infiltration and collagen deposition in a mouse model of skin fibrosis. 
Our results indicate that the anti-inflammatory and pro-fibrotic activity of 5-HT is primarily mediated 
through the 5-HT7R-PKA axis, and that 5-HT7R contributes to pathology in fibrotic diseases.
Serotonin (5-hydroxytryptamine, 5-HT) is a monoamine neurotransmitter derived from L-tryptophan via a 
rate-limiting reaction catalyzed by tryptophan hydroxylases (TPH1 in periphery, TPH2 in brain)1,2. Brain-derived 
5-HT controls mood, behavior, sleep, blood pressure and thermoregulation3 whereas peripheral 5-HT regulates 
vascular and heart functions4 and gastrointestinal mobility5. Enterochromaffin cells in the gastrointestinal tract 
produce 90% of the human body’s 5-HT6, which is actively taken up by blood platelets and stored in dense gran-
ules. Upon platelet activation, released 5-HT modifies vascular smooth muscle tone, promotes proliferation of 
smooth muscle cells7, hepatocytes8 and endothelial cells9, and critically contributes to wound healing. All 5-HT 
actions are exerted through engagement of seven types of receptors (5-HT1-7R) which, except for 5-HT3R, 
belong to the G protein-coupled superfamily of receptors10. 5-HT also functions as a regulator of immune and 
inflammatory responses11. 5-HT modulates T-cell activation, proliferation and differentiation12 and modifies 
cytokine production in a cell type-dependent manner13–16. The regulatory role of 5-HT in inflammation is illus-
trated by the pathological consequences of its altered production or absence in chronic inflammatory diseases. 
5-HT contributes to Pulmonary Arterial Hypertension (PAH)17, atopic dermatitis18 and systemic sclerosis19, and 
modifies the outcome of inflammatory gut disorders20–25. 5-HT also favors colon cancer angiogenesis26 and neu-
roendocrine neoplasms proliferation27, and its absence increases pathologic scores in collagen-induced arthri-
tis28. The close link between 5-HT and chronic inflammatory pathologies29 is in line with the anti-inflammatory 
actions of selective 5-HT reuptake inhibitors (SSRI) like fluoxetine30,31. Further supporting the 5-HT/inflam-
mation link, 5-HT2BR has been shown to mediate the effects of 5-HT on tissue fibrosis19 and PAH17, 5-HT7R 
mediates the 5-HT contribution to gut inflammation in IBD models20,22,23, and 5-HT3R or 5-HT4R ligands reduce 
inflammatory reactions during postoperative ileus32,33.
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Macrophages are critical for maintaining tissue homeostasis and promoting the initiation and resolution of 
inflammatory processes. The balance between pro- and anti-inflammatory (resolving) macrophages is required 
for restoring tissue homeostasis34–36, and its deregulation leads to chronic inflammatory diseases37,38. Since mac-
rophages rapidly adapt their functions to micro-environmental stimuli (e.g., cytokines, growth factors, pathogen- 
and damage-associated molecular patterns)34–38, targeting macrophages is currently proposed as a therapeutic 
approach for chronic inflammatory diseases37. Not surprisingly, some of the effects of 5-HT on inflammation are 
mediated through direct and indirect actions on myeloid cells17,26,32,33. Further supporting this relationship, bone 
marrow-derived cells are responsible for the contribution of 5-HT and 5-HT7R to intestinal inflammation22, and 
macrophages mediate the anti-inflammatory action of SSRI30,39.
We have previously demonstrated that human pro-inflammatory and anti-inflammatory macrophages40–43 
exhibit a distinct profile of 5-HT receptors, and that 5-HT2BR and 5-HT7R shape macrophage effec-
tor functions towards the anti-inflammatory side44. To dissect the molecular mechanisms underlying the 
inflammation-modulating action of 5-HT, we undertook the determination of the 5-HT-dependent tran-
scriptome of human macrophages. 5-HT rapidly altered the human macrophage transcriptome towards a 
growth-promoting, anti-inflammatory and pro-fibrotic gene profile, whose acquisition was dependent on the 
5-HT7R -PKA signaling axis. Moreover, and in line with these findings, Htr7−/− mice exhibited significantly 
reduced macrophage accumulation and collagen deposition in a bleomycin-induced model of skin fibrosis.
Results
5-HT promotes the expression of an anti-inflammatory gene profile and inhibits pro-inflam-
matory cytokine production. To determine the 5HT-dependent transcriptome of human macrophages, a 
global gene expression analysis was performed on human monocyte-derived macrophages (M-MØ) exposed to 
5-HT for 6 hours (Fig. 1A), a time at which exposure to 5-HT modifies the LPS-induced production of inflamma-
tory cytokines (see below). Transcriptional profiling revealed that 5-HT increases the expression of 170 annotated 
genes (p < 0.01; log2 ratio 5-HT/untreated ≥0.6) and downregulated the expression of 41 genes (p < 0.01; log2 
ratio 5-HT/untreated ≤ −0.6) (Supplementary Table I). Further filtering (normalized expression levels higher 
than 100 in untreated or 5-HT-treated M-MØ, and p < 0.0017 for the M-MØ vs. M-MØ + 5-HT comparison) 
identified 74 genes upregulated and 14 genes downregulated upon 5-HT exposure (Table 1) (Fig. 1B). Analysis of 
independent 5-HT-treated M-MØ samples confirmed the microarray data and revealed distinct kinetics for the 
Figure 1. Serotonin promotes the acquisition of an anti-inflammatory gene profile and conditions human 
macrophages for diminished LPS-stimulated proinflammatory cytokine production. (A) Experimental 
design of the gene profiling experiment. (B) Number of annotated genes whose expression is upregulated 
or downregulated in M-MØ exposed to 5-HT for 6 hours (p < 0.0017; Upregulated, log2 M-MØ + 5-HT/
M-MØ > 0.6; Downregulated, log2 M-MØ + 5-HT/M-MØ < −0.6). (C) Relative expression of the indicated 
genes in non-treated M-MØ (-) or M-MØ treated with 5-HT (5HT) for 2, 4, 6 and 12 hours. Results are 
expressed as the mRNA level of each gene relative to the GAPDH mRNA level in the same sample (n = 3; 
*p < 0.05). (D) Gene ontology analysis of the set of genes upregulated by 5-HT in M-MØ, as determined using 
the ENRICHR tool and the indicated databases [combined score = log(p-value) x z-score]. (E) GSEA on the “t 
statistic-ranked” list of genes obtained from the 5-HT-treated M-MØ versus M-MØ limma analysis, using the 
proinflammatory (left panel) and anti-inflammatory (right panel) gene sets previously defined48. Vertical black 
lines indicate the position of each of the genes comprising the “Pro-inflammatory” and “Anti-inflammatory” 
gene sets. (F) Production of IL-12p40, TNFα and Activin A by non-treated (-) or 5-HT-pretreated (6 h) LPS-
stimulated (18 h) M-MØ, as determined by ELISA (n = 12; *p < 0.05; **p < 0.01).
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probeid M-MØ M-MØ + 5HT
log2.fold 
M-MØ + 5HT/M-MØ t pval adj.pval genesymbol
A_23_P19333 80.05 344.74 2.0767 16.5371 0 0.192 TREM1
A_23_P401106 154.79 2069.16 3.6833 14.6249 0 0.192 PDE2A
A_23_P416711 51.15 137.60 1.4367 14.5716 0 0.192 ST6GALNAC3
A_23_P208900 275.45 686.62 1.3333 14.3717 0 0.192 SEMA6B
A_23_P32404 410.56 963.29 1.2367 13.1219 1.0000E-04 0.2092 ISG20
A_23_P132515 102.95 300.13 1.55 12.9583 1.0000E-04 0.2092 SIDT1
A_23_P257649 331.87 745.56 1.1767 12.2964 1.0000E-04 0.2138 RBP1
A_23_P373724 55.60 115.94 1.0967 11.7738 1.0000E-04 0.2138 PPFIBP1
A_24_P49260 120.84 254.30 1.14 11.5085 1.0000E-04 0.2138 SPTLC3
A_23_P154605 3414.30 7447.51 1.1567 10.6682 2.0000E-04 0.2138 SULF2
A_23_P85453 45.04 102.33 1.2633 10.2964 2.0000E-04 0.2138 CD244
A_24_P32085 269.48 651.45 1.2633 10.2497 2.0000E-04 0.2138 MOB3B
A_33_P3352578 74.65 140.30 0.93 10.043 2.0000E-04 0.2138 CLEC4D
A_23_P321354 389.53 744.31 0.9467 10.037 2.0000E-04 0.2138 TMEM71
A_33_P3333436 78.19 169.81 1.1033 9.9911 2.0000E-04 0.2138 SGSM3
A_23_P69109 1470.47 2684.51 0.8667 9.957 2.0000E-04 0.2138 PLSCR1
A_24_P349547 218.04 750.66 1.9733 9.8847 2.0000E-04 0.2138
A_33_P3322288 101.13 372.80 1.95 9.6901 2.0000E-04 0.2138 AZI2
A_24_P132383 491.79 927.06 0.94 9.3149 3.0000E-04 0.2138 GIMAP8
A_24_P93703 371.19 656.60 0.8167 8.9764 3.0000E-04 0.2138 TMEM198B
A_24_P324674 492.95 846.92 0.7767 8.9556 3.0000E-04 0.2138 LY9
A_23_P414654 56.39 113.19 0.9633 8.9112 3.0000E-04 0.2138 RAB37
A_24_P245379 51.84 148.73 1.4133 8.8935 3.0000E-04 0.2138 SERPINB2
A_23_P72117 446.16 1126.78 1.2967 8.8485 4.0000E-04 0.2138 SMPDL3A
A_24_P296508 702.06 1395.79 0.9533 8.7928 4.0000E-04 0.2138 SLC43A2
A_32_P161762 69.56 124.60 0.8667 8.7471 4.0000E-04 0.2138 RUNX2
A_23_P166297 227.26 450.70 0.9833 8.6544 4.0000E-04 0.2138 ABCG1
A_23_P428129 407.37 1022.43 1.32 8.6251 4.0000E-04 0.2138 CDKN1C
A_23_P102731 127.71 316.19 1.2833 8.6233 4.0000E-04 0.2138 SMOX
A_23_P404481 116.49 243.45 1.1133 8.5894 4.0000E-04 0.2138 S1PR1
A_33_P3226050 548.01 953.06 0.8 8.4776 4.0000E-04 0.2138 GATSL3
A_23_P10559 264.88 447.64 0.75 8.4521 4.0000E-04 0.2138 AATK
A_33_P3240843 170.64 314.95 0.8833 8.4384 4.0000E-04 0.2138 TMEM71
A_33_P3382560 7622.06 15383.62 1.06 8.424 4.0000E-04 0.2138 RPL23A
A_23_P25503 2952.57 6154.31 1.0633 8.4164 5.0000E-04 0.2138 FNDC3A
A_23_P86653 11484.56 19458.03 0.77 8.3019 5.0000E-04 0.2193 SRGN
A_23_P15108 532.44 913.10 0.77 8.1222 5.0000E-04 0.2193 YPEL3
A_23_P37375 217.10 359.90 0.7433 8.0574 5.0000E-04 0.2193 RPS6KA5
A_23_P89570 551.51 948.42 0.7633 8.0314 6.0000E-04 0.2193 ZMYND15
A_33_P3236177 703.17 1139.93 0.6967 7.9894 6.0000E-04 0.2193 ANG
A_23_P170453 4108.14 10205.73 1.4933 7.968 6.0000E-04 0.2193 CST5
A_33_P3273885 409.11 870.16 1.0067 7.9645 6.0000E-04 0.2193
A_33_P3323722 2078.85 4415.23 1.0967 7.9589 6.0000E-04 0.2193 ARL4C
A_23_P59637 957.90 1874.73 0.96 7.9163 6.0000E-04 0.2193 DOCK4
A_23_P154849 87.31 145.08 0.7267 7.9088 6.0000E-04 0.2193 OLIG1
A_23_P167920 117.43 211.91 0.8467 7.7999 6.0000E-04 0.2296 DLL1
A_24_P315184 9659.77 16932.61 0.8333 7.7041 7.0000E-04 0.2387 NBEAL1
A_32_P117464 190.00 365.73 0.97 7.6492 7.0000E-04 0.2392 MB21D2
A_33_P3422294 101.01 288.34 1.4233 7.6364 7.0000E-04 0.2392
A_33_P3317431 1153.70 2714.24 1.3067 7.5237 8.0000E-04 0.2392
A_23_P110445 129.59 225.31 0.8067 7.5107 8.0000E-04 0.2392 APBB3
A_23_P23438 741.59 1400.56 0.9633 7.4906 8.0000E-04 0.2392 SEMA4A
A_23_P57760 101.41 159.07 0.6567 7.4768 8.0000E-04 0.2392 ACPL2
A_33_P3351775 79.06 130.10 0.6867 7.4673 8.0000E-04 0.2392
A_33_P3227716 820.46 1369.66 0.7333 7.4591 8.0000E-04 0.2392 GATSL3
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5-HT-upregulated genes. As shown in Fig. 1C, EREG expression was maximally upregulated only two hours after 
exposure to 5-HT, while other genes (TREM1, MET, THBS1) exhibited maximal level of up-regulation 4–6 hours 
after 5-HT treatment. Therefore, 5-HT modifies the gene signature of human macrophages and its effects can be 
detected as early as 2 hours after exposure to the neurotransmitter.
Gene ontology analysis supported the relevance of the transcriptomic data because the 5-HT-upregulated gene 
set included a significant percentage of genes whose expression is increased by serotonin receptors agonists like 
co-dergocrine mesilate (adj p = 2.9 × 10−10) and pergolide (adj p = 3.03 × 10−8) (Fig. 1D). In fact, pergolide is an 
agonist for 5-HT2BR that causes valvular heart disease45,46 and M-MØ express functional 5-HT2BR receptors44. 
Besides, 5-HT enhanced the expression of genes positively regulated by prostaglandins (Alprostidil, Dinoprost), 
probeid M-MØ M-MØ + 5HT
log2.fold 
M-MØ + 5HT/M-MØ t pval adj.pval genesymbol
A_23_P76969 785.27 2508.70 1.6 7.4097 8.0000E-04 0.2392 SIPA1L1
A_23_P115011 59.66 102.35 0.8333 7.3499 8.0000E-04 0.2392 ADAMTSL4
A_32_P87697 29475.87 46802.86 0.6833 7.3421 8.0000E-04 0.2392 HLA-DRA
A_23_P55356 279.95 489.77 0.82 7.2414 9.0000E-04 0.2392 VMO1
A_23_P214139 349.66 647.84 0.8833 7.2258 9.0000E-04 0.2392 REV3L
A_33_P3259557 296.93 544.75 0.8333 7.1249 0.001 0.2435 TMEM198B
A_23_P79518 166.63 375.23 1.0967 7.111 0.001 0.2435 IL1B
A_24_P370172 236.53 391.70 0.72 7.0777 0.001 0.2457 LILRA5
A_23_P152791 163.03 270.51 0.75 6.851 0.0011 0.2668 SLC16A6
A_23_P400378 512.19 844.84 0.8067 6.8421 0.0011 0.2668 GPBAR1
A_23_P85716 2690.03 4201.95 0.6933 6.8414 0.0011 0.2668 FCGR2A
A_33_P3413840 121.69 228.70 0.9067 6.8214 0.0012 0.2668 GK
A_33_P3372727 54.20 141.80 1.44 6.8087 0.0012 0.2668 SEMA5A
A_23_P38795 1232.70 2077.44 0.8033 6.7376 0.0012 0.2692 FPR1
A_33_P3352098 11435.65 17831.64 0.6367 6.7192 0.0012 0.2692 MS4A7
A_33_P3315320 70.38 106.96 0.6 6.7149 0.0012 0.2692 CNTD1
A_23_P55020 656.97 1013.28 0.6133 6.659 0.0013 0.2725 CD300LF
A_33_P3415191 182.14 313.76 0.78 6.6105 0.0013 0.2733 ATP8B1
A_33_P3232557 119.84 206.66 0.7833 6.5667 0.0014 0.2733 DLGAP3
A_23_P41114 878.89 1323.40 0.6167 6.4491 0.0015 0.2733 CSTA
A_23_P201747 114.55 205.24 0.7933 6.4307 0.0015 0.2733 PADI2
A_33_P3236267 228.15 690.87 1.7367 6.4271 0.0015 0.2733 KCNQ1OT1
A_23_P380998 165.10 269.18 0.74 6.4024 0.0015 0.2733 R3HDM1
A_23_P60166 395.34 627.24 0.6367 6.3945 0.0016 0.2733 DEPTOR
A_23_P215744 91.56 144.62 0.7067 6.3883 0.0016 0.2733 CTTNBP2
A_23_P258108 11895.64 19363.83 0.7267 6.3718 0.0016 0.2733
A_33_P3386132 397.26 623.42 0.66 6.3502 0.0016 0.2733 C2orf49
A_24_P110273 676.36 1044.92 0.6333 6.3217 0.0016 0.2733
A_23_P25566 4726.99 7713.17 0.7067 6.3212 0.0016 0.2733 GPR183
A_23_P67896 269.49 137.51 −0.9233 −6.3894 0.0016 0.2733 SCN3A
A_23_P125204 492.06 317.00 −0.6133 −6.4729 0.0015 0.2733 OR10G8
A_33_P3232955 920.03 555.00 −0.77 −6.662 0.0013 0.2725 F2RL3
A_32_P134290 1591.48 1022.82 −0.65 −6.7639 0.0012 0.2689 ZCCHC2
A_23_P62967 1743.65 1144.21 −0.6033 −6.7737 0.0012 0.2689 DISC1
A_33_P3512350 675.48 399.65 −0.7567 −6.9789 0.0011 0.2531 LOC339807
A_23_P340848 1536.35 979.80 −0.6667 −7.0574 0.001 0.246 PTGIR
A_23_P103034 214.84 114.56 −0.9067 −7.2742 9.0000E-04 0.2392 CRYBA4
A_23_P328545 440.40 259.98 −0.7633 −8.0807 5.0000E-04 0.2193 GABRP
A_23_P404162 100.99 46.26 −1.0767 −8.2829 5.0000E-04 0.2193 HDAC9
A_23_P81441 1493.93 874.24 −0.76 −8.7105 4.0000E-04 0.2138 C5orf20
A_33_P3380383 4374.93 2579.19 −0.8067 −8.8739 4.0000E-04 0.2138 TIFAB
A_23_P91095 523.44 291.00 −0.8367 −9.6298 2.0000E-04 0.2138 CD28
A_32_P155666 716.76 350.13 −1.0733 −9.703 2.0000E-04 0.2138 ECEL1
Table 1. Gene expression analysis on untreated (M-MØ) and 5-HT-treated (10 μM, 6h) M-MØ (M-MØ+5HT), 
where the normalized fluorescence of each probe (probeid) and the corresponding gene symbol (genesymbol) 
is indicated. Probes are ordered according to the t-value (t) of the M-MØ+5HT/ M-MØ ratio, and the p values 
obtained after adjusting for multiple hypotheses testing (adj.pval) are shown.
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dopamine (Quinpirole, co-dergocrine mesilate), and adrenergic (Orciprenaline, Tetryzoline, (-)-isoprenaline) 
receptor ligands (Fig. 1D). Regarding biological processes, gene ontology analysis revealed that 5-HT-upregulated 
genes are significantly enriched in genes involved in chemotaxis (adj p = 1.8 × 10−3), cAMP catabolic process (adj 
p = 1.3 × 10−2) and regulation of cytokine production (adj p = 1.7 × 10−2), as well as in genes regulated by IL-10 
(adj p = 8.3 × 10−6 and adj p = 4.2 × 10−5) and TGFβ (adj p = 2.7 × 10−3), and negatively regulated upon IFNAR1 
stimulation (adj p = 7.0 × 10−5) (Fig. 1D).
The availability of the 5-HT-dependent transcriptome in M-MØ allowed us to address the global effect 
of 5-HT on the macrophage transcriptome. We have previously determined the gene expression profiles of 
IL-10-producing anti-inflammatory (M-MØ) and TNF-α-producing pro-inflammatory (GM-MØ) human 
macrophages47–49, and identified two sets of 150 genes that best define their corresponding transcriptomes 
(“Anti-inflammatory gene set” for M-MØ, and “Pro-inflammatory gene set” for GM-MØ)47,48. Analysis of the 
expression of both gene sets in 5-HT-treated macrophages using Gene Set Enrichment Analysis (GSEA) revealed 
that, compared to untreated cells, the transcriptome of 5-HT-treated macrophages shows a significantly higher 
expression of the “Anti-inflammatory gene set” (FDR q value = 0.000) together with a significantly lower expres-
sion of the “Pro-inflammatory gene set” (FDR q value = 0.012) (Fig. 1E). In fact, genes within the leading edge 
of the “anti-inflammatory gene set” included CD163L1, HTR2B, and IL10, whose expression is closely linked 
to M-CSF-driven anti-inflammatory polarization44,48,49 (Fig. 1E, right panel and data not shown). At the func-
tional level, and in line with GSEA results, 5-HT pretreatment (6 hours) led to a significant reduction in the 
LPS-induced production of IL-12p40, TNFα and Activin A of M-MØ (Fig. 1F). Therefore, 5-HT promotes the 
acquisition of an anti-inflammatory gene profile and conditions macrophages for a diminished pro-inflammatory 
response towards pathogenic stimuli.
5-HT modulates macrophage transcriptome and function primarily via the 5-HT7R-PKA sign-
aling axis. To determine the receptors responsible for the acquisition of the 5HT-dependent transcriptional 
and functional profile in 5-HT7R+/5-HT2BR+ M-MØ44, macrophages were exposed to 5-HT in the presence of 
5-HT7R antagonists SB26997050 or SB25871951, or the 5-HT2BR antagonist SB20474152. Whereas blockade of 
5-HT2BR had no effect (Supplementary Figure 1), 5-HT7R antagonists prevented or significantly inhibited the 
Figure 2. The acquisition of the 5-HT-dependent gene signature of human M-MØ is mediated by the 5-HT7R 
receptor. (A) Relative expression of the indicated genes in non-treated (-) or 5-HT-treated (5HT, 6 h) M-MØ 
and either in the absence (-) or in the presence of the 5-HT7R antagonists SB269970 or SB258719. Results are 
expressed as the mRNA level of each gene relative to the TBP mRNA level in the same sample (n = 6; *p < 0.05; 
**p < 0.01; ***p < 0.001). (B) Relative expression of the indicated genes in M-MØ either non-treated (-) or 
treated for 6 h with 5-HT or the 5-HT7R agonist AS19. Results are expressed as the mRNA level of each gene 
relative to the TBP mRNA level in the same sample (n = 6; *p < 0.05).
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5-HT-dependent up-regulation of PDE2A, THBS1, MET, TREM1, SERPINB2, ISG20, AZI2 and S1PR1 (Fig. 2A). 
Although to a lower extent than 5-HT, the 5-HT7R agonist AS19 was capable of enhancing the expression of 
PDE2A and THBS1 (Fig. 2B), further supporting the involvement of 5-HT7R in the 5-HT-dependent gene expres-
sion changes in human macrophages. However, since AS19 had no effect on other 5-HT-regulated genes (MET) 
(Fig. 2B), additional receptors might also contribute to the acquisition of the 5-HT-dependent gene signature.
Since 5-HT7R engagement leads to increased intracellular levels of cAMP53, whose effectors include 
PKA and “Exchange factor directly activated by cAMP” (Epac), we next assessed the effect of cAMP analogs 
(BrcAMP, dBrcAMP) and modifiers of cAMP-initiated signaling (6Bnz, 8cPT, RP8) on the acquisition of the 
5-HT-dependent gene signature in M-MØ. The cAMP analogs BrcAMP and dBrcAMP greatly enhanced the 
expression of genes upregulated by 5-HT (PDE2A, TREM1, THBS1, MET) (Fig. 3A). Similar changes in the 
expression of these genes were seen in M-MØ exposed to the PKA-specific activator 6-Bnz-cAMP (Fig. 3A), while 
the Epac activator 8-pCPT had no effect (Fig. 3A). Moreover, the positive effect of 5-HT on the expression of 
5-HT-upregulated genes was significantly blunted or inhibited in the presence of the PKA inhibitor RP8 (Fig. 3B). 
Therefore, 5-HT shapes M-MØ gene expression primarily via engagement of 5-HT7R and activation of PKA.
Since the 5-HT7R-PKA axis mediates the expression of the 5-HT-dependent M-MØ transcriptome, we next 
evaluated whether this signaling axis contributes to the inhibitory effect of 5-HT on the LPS-induced production 
of inflammatory cytokines by M-MØ, which produce undetectable levels of TNFα and IL-12p40 in the absence 
of stimulation44. Both 5-HT7R antagonists (SB269970 and SB258719) dose-dependently reversed the inhibitory 
action of 5-HT on the production of TNFα and IL-12p40 induced by LPS (Fig. 4A), while the 5-HT7R ago-
nist AS19 (1 μM) mimicked the effect of 5-HT on the LPS-induced expression of TNFα and IL-12p40 (Fig. 4B). 
Furthermore, the inhibitory effect of 5-HT on the LPS-induced production of TNFα and IL-12p40 was signif-
icantly reduced in the presence of the PKA inhibitor RP8 (Fig. 4C). Thus, 5-HT conditions macrophages for 
a diminished production of pro-inflammatory cytokines primarily via engagement of 5-HT7R and activation 
of PKA. As a whole, this set of results demonstrates that the 5-HT7R-PKA axis mediates the acquisition of the 
5-HT-dependent gene and cytokine profile in human macrophages.
Figure 3. The acquisition of the 5-HT/5-HT7R-dependent gene signature of human M-MØ is mediated by 
PKA. (A) Relative expression of the indicated genes in M-MØ either untreated (-) or treated for 6 h to the PKA 
activators BrcAMP, dBrcAMP or 6Bnz, or to the Epac activator 8cPT. Results are expressed as the mRNA level 
of each gene relative to the GAPDH mRNA level in the same sample (n = 3; *p < 0.05). (B) Relative expression 
of the indicated genes in non-treated (-) or 5-HT-treated (5HT, 6 h) M-MØ and either in the absence (-) or in 
the presence of the PKA inhibitor RP8. Results are expressed as the mRNA level of each gene relative to the TBP 
mRNA level in the same sample (n = 6; *p < 0.05; **p < 0.01).
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5-HT impairs type I IFN-dependent gene and chemokine expression through the 5-HT7R-PKA 
axis. To gain further biological insights from the 5-HT-dependent M-MØ transcriptome, we performed 
GSEA on the 5-HT-induced gene profile using gene sets contained in the Molecular Signature databases avail-
able at the GSEA Website. GSEA on the 5-HT-dependent transcriptome using the gene sets revealed a signifi-
cant enrichment of the “hallmark IFNγ response” (FDR q value = 0.102) and “hallmark IFNα response” (FDR q 
value = 0.187) gene sets within the genes upregulated by 5-HT (Fig. 5A). In agreement with the GSEA data, the 
mRNA levels of type I IFN-dependent genes (CXCL10, CXCL11, IDO1, RSAD2, IL27 and IFIT2) (Fig. 5B) and the 
production of the type I IFN-dependent chemokine CXCL10 (Fig. 5C) were significantly reduced in LPS-treated 
M-MØ that had been pre-treated for 6 hours with 5-HT. Moreover, M-MØ also produced reduced levels of 
CXCL10 in response to IFNβ if previously exposed to 5-HT (Fig. 5D). The decrease in LPS- or IFNβ-induced 
CXCL10 production caused by 5-HT exposure correlated with a reduced activation of STAT1 in response to 
either LPS or IFNβ (Fig. 5E,F), further supporting the 5-HT´s ability to limit macrophage responses to type I 
IFN. Importantly, the ability of 5-HT to limit the expression of type I IFN-responsive genes is also mediated by 
the 5-HT7R-PKA axis, as it was abolished by either 5-HT7R antagonists (SB269970 and SB258719) or the PKA 
inhibitor RP8 (Fig. 5G).
5-HT also promotes pro-fibrotic gene expression in human macrophages. Additional GSEA 
results evidenced that a short-term (6 h) exposure to 5-HT causes a global upregulation of the “Angiogenesis” gene 
sets, as well as a very significant downregulation of the “Cholesterol homeostasis” and “Fatty Acid Metabolism” 
genes sets (Supplementary Figure 2). Furthermore, 5-HT treatment led to a significant upregulation of the “TGFβ 
signaling” gene set (FDR q-val = 0.126) (Fig. 6A). In line with the GSEA data, 5-HT was found to induce a signif-
icant increase in TGFB1 mRNA (Fig. 6B). Like most 5-HT-upregulated genes, the enhanced expression of TGFB1 
mRNA was prevented by 5-HT7R antagonists (Fig. 6B) and did not occur in the presence of the PKA inhibitor 
RP8 (Fig. 6C). More importantly, 5-HT treatment of M-MØ resulted in a significantly increase production of 
TGFβ1 (Fig. 6D). Therefore, engagement of 5-HT7R by 5-HT promotes the production of TGFβ1 as well as the 
acquisition of a pro-fibrotic gene signature in human macrophages.
Lack of Htr7 results in diminished macrophage infiltration and pathology in a mouse model 
of skin fibrosis. Macrophages exert critical functions during tissue repair after injury but their deregulated 
polarization can also result in excessive scarring and chronic fibrosis54,55. In fact, macrophages are important cells 
for the onset of scleroderma56,57 and pulmonary fibrosis58,59, and their deregulated polarization results in fibrosis 
in muscle60. Given the 5-HT/5-HT7R-upregulated expression of TGFβ1 in human macrophages, and to analyze 
the contribution of 5-HT7R to skin fibrosis development, we assessed the effect of Htr7 gene ablation in the 
Figure 4. The inhibitory effect of 5-HT on the LPS-induced pro-inflammatory cytokine production of human 
macrophages is dependent on 5-HT7R and PKA. (A) Production of LPS-stimulated IL-12p40 and TNFα by 
M-MØ non-treated (-) or pretreated with 5-HT (6 h) in the presence or absence of the 5-HT7R antagonists 
SB269970 or SB258719 (n = 6; *p < 0.05; **p < 0.01; ***p < 0.001). (B) Production of LPS-stimulated IL-12p40 
and TNFα by M-MØ non-treated (-) or pretreated (6 h) with either 5-HT (5HT) or the 5-HT7R agonist AS19 
(n = 6; *p < 0.05; **p < 0.01). (C) Production of LPS-stimulated IL-12p40 and TNFα by M-MØ non-treated 
(-) or pretreated with 5-HT (5HT, 6 h) in the presence or absence of the PKA inhibitor RP8 (n = 6; *p < 0.05; 
**p < 0.01).
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Figure 5. Serotonin modifies the type I IFN-dependent gene profile and impairs the response of human 
macrophages to type I IFN through 5-HT7R and PKA. (A) GSEA on the “t statistic-ranked” list of genes 
obtained from the 5-HT-treated M-MØ versus M-MØ limma analysis, using the “Hallmark_Interferon_
gamma_response” (left panel) and the “Hallmark_Interferon_alpha_response” (right panel) gene sets. (B) 
Expression of the indicated genes in untreated (-) or 5-HT-pretreated (5HT, 6 h) LPS-stimulated (4 h) M-MØ, 
as determined by qRT-PCR. Results are expressed as the mRNA level of each gene relative to the level of TBP 
mRNA in the same sample (n = 3; *p < 0.05; **p < 0.01). (C) Production of LPS-stimulated CXCL10 by 
untreated (-) M-MØ and 5-HT-treated M-MØ (5HT, 6 h) exposed to LPS for 18 h (n = 12; *p < 0.05).  
(D) Production of IFNβ1-stimulated CXCL10 by M-MØ non-treated (-) or pretreated with 5-HT (5HT, 6 h), 
using the indicated concentrations of IFNβ1 (n = 13; *p < 0.05). (E) Levels of IkBα and phosphorylated STAT1 
in untreated (-) M-MØ and 5-HT-treated M-MØ (5HT, 6 h), after stimulation with LPS for the indicated 
periods of time (left panel). Protein loading was normalized using a monoclonal antibody against GAPDH. 
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mouse model of bleomycin-induced dermal fibrosis that mimics histological features of human scleroderma61. 
To this end we first determined Htr7 expression of in mouse macrophages in vitro and in vivo. Htr7 mRNA was 
readily detected in liver Kupffer cells and peritoneal F4/80+ macrophages, with Htr7a being the predominant 
splicing isoform in both cases (Supplementary Figure 3A). Unlike human monocyte-derived macrophages, Htr7 
mRNA was only detected in murine pro-inflammatory GM-MØ, where also Htr7a was the predominant iso-
form (Supplementary Figure 3B). Also in marked contrast with human macrophages, where HTR7 mRNA is 
greatly reduced in response to LPS44, macrophage Htr7 mRNA was greatly upregulated after LPS stimulation 
(Supplementary Figure 3C).
Once the presence of Htr7 mRNA had been demonstrated in murine macrophages, the effect of Htr7 gene 
deletion in a mouse model of fibrosis was assessed. Whereas no histological differences in collagen stained area 
were observed between saline-treated Htr7−/− and WT mice, a significant increase in skin collagen content was 
observed after bleomycin injection in WT mice (Fig. 6E). Conversely, Htr7−/− mice appeared protected from 
bleomycin-induced fibrosis since significantly reduced collagen area content was observed in bleomycin-treated 
Htr7−/− skin compared to WT skin (Fig. 6E). In addition, myofibroblast differentiation evaluated as α-SMA 
expression, was also significantly reduced in Htr7−/− compared to WT mice (Fig. 6E). Likewise, a significantly 
lower infiltration of F4/80+ cells was found in bleomycin-treated Htr7−/− mice (Fig. 6E). In addition, bleomycin 
treatment significantly enhanced α-SMA expression in WT mice but not in Htr7−/− mice (Fig. 6E). Therefore, and 
in line with the transcriptional results in human macrophages, 5-HT7R expression contributes to macrophage 
accumulation and fibrosis in the bleomycin model of skin fibrosis.
Discussion
Macrophages exhibit a huge phenotypic and functional heterogeneity, and their effector functions (“polariza-
tion state”) are determined by the integration of the intracellular signals initiated by the surrounding extracel-
lular cues and stimuli. Elimination of inflammatory insults requires the balanced and sequential dominance of 
pro-inflammatory and anti-inflammatory/resolving macrophages62 whose deregulation leads to chronic inflam-
matory diseases63–65. Given their critical role in the initiation and resolution of inflammation, modulation of the 
macrophage polarization state has been proposed as a therapeutic approach for numerous chronic inflammatory 
pathologies37. While the physiological processes regulated by 5-HT (cell proliferation, tissue repair, inflamma-
tion) are also critically modulated by macrophages66, the influence of 5-HT on macrophage plasticity is not yet 
completely understood11. Based on the ability of 5-HT to modulate the macrophage cytokine profile44, we under-
took the determination of the 5-HT-dependent human macrophage transcriptome. Our results indicate that 
5-HT conditions macrophages for impaired production of pro-inflammatory cytokines and type I IFN-inducible 
cytokines, and also shapes the macrophage gene signature towards the acquisition of an anti-inflammatory and 
pro-fibrotic gene profile, with all these effects being primarily mediated by the 5-HT7R-PKA axis.
The link between 5-HT and fibroblast proliferation/fibrosis has been known to be primarily mediated by 
the 5-HT2BR receptor, which induces extra-cellular matrix synthesis in fibroblasts19 and whose over-activation 
leads to excessive proliferation of cardiac valves fibroblasts and severe cardiac pathologies67–69. Our results reveal 
that 5-HT7R is a primary mediator of the pro-fibrotic action of 5-HT on human macrophages because 5-HT7R 
antagonists and inhibitors of 5-HT7R-initiated signaling block the acquisition of the pro-fibrotic gene signature 
as well as the 5-HT-upregulated production of TGFβ1 in human macrophages. The pro-fibrotic action of 5-HT7R 
is further supported by in vivo results, as Htr7−/− mice exhibit diminished pathology (lower collagen deposition 
and F4/80+ cell infiltration) in the bleomycin-induced model of skin fibrosis. Macrophages play a critical role in 
fibrotic processes54. In fact, elimination of macrophages expressing Folr2, a myeloid-specific protein exclusively 
expressed by anti-inflammatory M-MØ70, greatly diminishes pathology in the bleomycin-induced experimental 
skin fibrosis71. Therefore, it can be speculated that the absence of 5-HT7R in mouse macrophages contributes to 
the diminished skin pathology we have observed. Alternatively, other macrophage 5-HT7R-dependent functions 
might contribute to the reduced pathology seen in Htr7−/− mice. Specifically, impaired migration of myeloid 
cells to the bleomycin-treated tissue might explain the reduced accumulation of F4/80+ cells in the damaged 
skin of Htr7−/− mice. This explanation would fit with the impaired migration of mouse bone marrow-derived 
dendritic cells from Htr7−/− mice72 and is supported by the significant 5-HT-dependent upregulation of genes 
involved in cell chemotaxis (Fig. 1D). However, these interpretations should be taken cautiously, because expres-
sion of 5-HT7R appears to be differentially regulated in mouse and human macrophages: 5-HT7R in human mac-
rophages is greatly downregulated by pathogenic stimuli like LPS44 whereas Ht7r expression in mouse myeloid 
cells is greatly upregulated by LPS72. In line with our findings, the 5-HT7R agonist LP-44 has been reported to 
reduce pro-inflammatory cytokine production in vivo in a carbon tetrachloride-induced rat model of liver fibro-
sis73, where the agonist was, however, also capable of inhibiting Tgfb1 mRNA73. The latter discrepancy between 
these results and ours might be explained by the use of different 5-HT7R agonists (5HT versus a chemical agonist) 
and animal models of fibrosis (bleomycin-induced mouse skin fibrosis versus carbon tetrachloride-induced rat 
liver fibrosis), but indicate a significant involvement of 5-HT7R in fibrotic responses.
Densitometric analysis of three independent experiments is shown in the right panels (n = 3; **p < 0.01). (F) 
Levels of phosphorylated STAT1 in untreated (-) M-MØ and 5-HT-treated M-MØ (5HT, 6 h), after stimulation 
with LPS or IFNβ1 (for 2 h). Protein loading was normalized using a monoclonal antibody against Vinculin. 
Densitometric analysis of three independent experiments is shown in the right panels (n = 3; *p < 0.05). (G) 
Production of LPS-stimulated CXCL10 by non-treated (-) M-MØ or M-MØ pretreated with 5-HT (5HT, 6 h) in 
the presence or absence of the 5-HT7R antagonists SB269970 or SB258719 (n = 6; *p < 0.05; ***p < 0.001) (left 
panel) or in the presence or absence of the PKA inhibitor RP8 (n = 6; **p < 0.01) (right panel).
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In peripheral tissues, 5-HT7R is expressed in smooth muscle cells of blood vessels and the gastrointesti-
nal tract, as well as in kidney, liver, pancreas and spleen74–76. Within the immune system, the functional con-
sequences of 5-HT7R ligation are far from clear. 5-HT7R on mouse naive T cells contributes to early T-cell 
activation12, whereas 5-HT7R on human monocytes has been reported to inhibit77 or enhance78 LPS-induced 
pro-inflammatory cytokine release. A similar controversy appears to exist regarding the in vivo role of Htr7, 
whose deletion has been reported to improve22 or exacerbate23 mouse gut inflammation. Our transcriptional 
results clarify this issue and demonstrate that 5-HT7R, acting through PKA, conditions macrophages towards 
the acquisition of a more anti-inflammatory and pro-fibrotic polarization state and for an impaired production of 
pro-inflammatory functions. As a consequence, our results place 5-HT7R as a potentially relevant molecule for 
modulation of macrophage effector functions under physiological and pathological settings.
The anti-inflammatory gene profile promoted by 5-HT/5-HT7R is compatible with the known signaling abil-
ity of 5-HT7R. Although 5-HT7R has been shown to activate NFκB in monocytes12,78, and ERK1/279, Akt80, 
p38MAPK and protein kinase Cε81, or the Cdc42-Gα12-SRF axis82 in various cell types, 5-HT7R couples posi-
tively to adenylate cyclase through activating Gαs, leading to increased cAMP levels and activation of PKA and 
Epac1/274. These cell-specific differences in 5-HT7R signaling might derive from the presence of distinct splicing 
isoforms or heterodimerization with other receptors83,84. In the case of human macrophages, where the three 
splicing isoforms can be detected at the mRNA level (data not shown), our results clearly establish PKA, and not 
Figure 6. 5-HT7R engagement promotes the acquisition of a pro-fibrotic gene signature in human 
macrophages and contributes to pathology-associated parameters in a mouse model of skin fibrosis. (A) GSEA 
on the “t statistic-ranked” list of genes obtained from the 5-HT-treated M-MØ versus M-MØ limma analysis, 
using the “TGFβ signaling” gene set. Black vertical lines indicate the position of each of the genes included 
within the “TGFβ signaling” Hallmark gene set. (B) Relative expression of TGFB1 mRNA in non-treated 
M-MØ (-) or M-MØ exposed to 5-HT (5HT, 6 h) in the absence or in the presence of the 5-HT7R antagonists 
SB269970 or SB258719. Results are expressed as the TGFB1 mRNA level relative to the TBP mRNA level in 
the same sample (n = 6; *p < 0.05). (C) Relative expression of TGFB1 mRNA in non-treated M-MØ (-) or 
M-MØ exposed to 5-HT (5HT, 6 h) in the absence or in the presence of the PKA inhibitor RP8. Results are 
expressed as the TGFB1 mRNA level relative to the TBP and HPRT1 mRNA level in the same sample (n = 6; 
*p < 0.05; **p < 0.01). (D) Production of TGFβ1 by non-treated M-MØ (-) or M-MØ treated with 5-HT (5HT) 
for 24 h. (n = 3; **p < 0.01). (E) Fibrosis was measured as the collagen Masson stained area (upper panel), 
immunohistochemistry analysis of activated fibroblasts (α-SMA+, middle panel) and number of F4/80+ cells 
per area (lower panel), in lesional skin from saline- or bleomycin-treated control and Htr7−/− mice. Shown 
are the mean and SEM of three independent experiments with 10 mice per group. Statistical significance was 
evaluated using Mann-Whitney U-test, (*p < 0.05; **p < 0.01). Representative skin sections stained are shown 
(bar, 50 μM).
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Epac1/2, as a major effector of 5-HT7R, as most of the transcriptional actions of 5-HT7R engagement by 5-HT 
can be abolished by PKA inhibitors and mimicked by PKA activators. Furthermore, the connexion between 
5-HT7R and PKA activation fits well with the global anti-inflammatory skewing induced by 5-HT via 5-HT7R 
because PKA leads to CREB activation, which favours the acquisition of a “M2 polarization state”62. In addition, 
cAMP-initiated signaling limits the effector functions of pro-inflammatory stimuli85,86, which is consistent with 
the reduced production of proinflammatory cytokines seen with 5-HT7R activation.
The ability of 5-HT to promote the acquisition of a pro-fibrotic and anti-inflammatory signature in human 
macrophages has relevant pathophysiological implications. While normal peripheral blood levels of 5-HT range 
between 0.7 and 2.5 μM87–91, 5-HT concentrations at the neuronal synapse have been estimated to reach the 
millimolar range92, and the available platelet serotonin is close to 20 μM93. Since platelets release serotonin dur-
ing inflammation as a means to activate endothelial cells and promote leukocyte adhesion and recruitment93, 
our findings on the macrophage polarizing effects of 10 μM 5-HT are physiologically relevant, especially at the 
initial stages of inflammatory responses. Besides, and regarding pathology, the serum levels of 5-HT detected in 
metastatic carcinoid tumors exceed 30 μM91, thus pointing to 5-HT as a factor that contributes to polarization 
of macrophages in serotonin-producing neuroendocrine tumors. Therefore, 5HT7R-regulated genes should be 
considered as potential targets to modify macrophage polarization under pathological settings.
Materials and Methods
Ethical statement. Ethical approvals for all blood sources and processes used in this study have been 
approved by the Centro de Investigaciones Biológicas Ethics Committees. Subjects gave written informed consent 
in accordance to the Declaration of Helsinki. All experiments were carried out in accordance with the approved 
guidelines and regulations.
All experiments on mice were conducted according to the Spanish and European regulations on care and 
protection of laboratory animals and were approved by the Consejo Superior de Investigaciones Científicas ethics 
committee.
Generation of human monocyte-derived macrophages and cell isolation and culture. Human 
peripheral blood mononuclear cells (PBMC) were isolated from buffy coats from normal donors over a 
Lymphoprep (Nycomed Pharma, Oslo, Norway) gradient according to standard procedures. Monocytes were 
purified from PBMC by magnetic cell sorting using CD14 microbeads (Miltenyi Biotech, Bergisch Gladbach, 
Germany). Monocytes (>95% CD14+ cells) were cultured at 0.5 × 106 cells/ml for 7 days in RMI supplemented 
with 10% fetal calf serum (FCS) (completed medium), at 37 °C in a humidified atmosphere with 5% CO2, and 
containing M-CSF (10 ng/ml) (ImmunoTools GmbH, Friesoythe, Germany) to generate monocyte-derived 
macrophages (M-MØ). Cytokine was added every two days. Before treatment with 5HT, M-MØ macrophages 
were maintained in serum-free medium for 48 hours, without a significant change in the level of expression of 
M-MØ-specific markers. Macrophage activation was accomplished with either ultrapure LPS (E. coli 055:B5, 
10 ng/ml, Invivogen, San Diego, CA), synthetic triacylated lipoprotein (Pam3CSK4, 10 μg/ml, Invivogen) or 
IFNγ (10–100 IU/ml, Miltenyi Biotech). Bone marrow-derived mouse macrophages were also generated using 
GM-CSF (mouse GM-MØ) or M-CSF (mouse M-MØ) as described previously94,95. RNA from mouse liver cells 
was obtained as previously described44. Isolation of mouse peritoneal mouse macrophages was done by magnetic 
cell sorting using F4/80-biotin and Streptavidin microbeads (Miltenyi Biotech). For activation, macrophages were 
treated with Escherichia coli 055:B5 LPS (100 ng/ml for mouse macrophages; 10 ng/ml for human macrophages) 
for 24 h. 5-HT was obtained from Sigma Aldrich and used at 10μM. 5-HT7R agonists AS19 was obtained from 
Tocris Bioscience and used at 1μM. 5-HT7R antagonists (SB269970 and SB258719 were purchased from Sigma 
Aldrich and Tocris Bioscience, respectively, and added at 10μM 1 hour before 5-HT treatment. cAMP analogues 
(BrcAMP and dBrcAMP) were used at 200μM and 50μM, respectively. The PKA activator 6BNZ-cAMP (6Bnz) 
and the EPAC-specific activator 8-pCPT-2′-O-Me-cAMP (8cPT) were obtained from Sigma Aldrich and used at 
200μM and 100μM, respectively. The PKA-specific inhibitor RP-8-CPT-cAMPs (RP8) was obtained from Biolog 
and used at 100μM.
ELISA. Culture supernatants from untreated or LPS-treated (24 h) human macrophages were assayed for 
the presence of cytokines using commercially available ELISA for human TNFα, IL-12p40 (BD Pharmingen), 
CXCL10, IL-10 (Biolegend), activin A and TGFβ (R&D Systems). ELISA was performed following the protocols 
supplied by the manufacturers.
Quantitative real-time RT-PCR. Oligonucleotides for selected genes were designed according to the 
Universal Probe Roche library system (Roche Diagnostics) for quantitative real time PCR (qRT-PCR). Total RNA 
was extracted using the RNeasy kit (Qiagen), retrotranscribed, and amplified in triplicates. Results were expressed 
relative to the expression level of TBP RNA. When indicated, results were expressed relative to the mean of the 
expression level of endogenous reference genes HPRT1, TBP and RPLP0. In all cases the results were expressed 
using the ΔΔCT method for quantitation.
Microarray analysis. Global gene expression analysis was performed on RNA obtained from untreated or 
5-HT-treated (10 μM, 6 h) M-MØ from three independent healthy donors. RNA was isolated using the RNeasy 
Mini kit (Qiagen, Germantown, MD) and labeled RNA used as a hybridization probe on Whole Human Genome 
Microarrays (Agilent Technologies, Palo Alto, CA). Only probes with signal values > 60% quantile in at least one 
condition were considered for the differential expression and statistical analysis. Statistical analysis for differ-
ential gene expression was carried out using empirical Bayes moderated t test implemented in the limma pack-
age (http://www.bioconductor.org). The p values were further adjusted for multiple hypotheses testing using the 
www.nature.com/scientificreports/
1 2SCIentIfIC RepoRtS | 7: 14761  | DOI:10.1038/s41598-017-15348-y
Benjamini-Hochberg method to control the false discovery rate96. All the above procedures were coded in R 
(http://www.r-project.org). Microarray data were deposited in the Gene Expression Omnibus (http://www.ncbi.
nlm.nih.gov/geo/) under accession GSE94608. Differentially expressed genes were analysed for annotated gene 
sets enrichment using the online tool ENRICHR (http://amp.pharm.mssm.edu/Enrichr/)97,98. Enrichment terms 
were considered significant when they had a Benjamini-Hochberg-adjusted p value < 0.05. For gene set enrich-
ment analysis (GSEA)99, the gene sets contained in the Molecular Signature databases available at the GSEA 
website, and the previously defined “Pro-inflammatory gene set” and “Anti-inflammatory gene set”48, which con-
tain the top and bottom 150 probes from the GM-MØ versus M-MØ limma analysis of the microarray data in 
GSE68061 (ranked on the basis of the value of the t statistic), were used.
Western blot. Cell lysates were obtained in RIPA buffer (10 mM Tris-HCl pH 8, 150 mM NaCl, 1% NP-40, 
2 mM Pefabloc, 2 mg/ml aprotinin/antipain/leupeptin/pepstatin, 10 mM NaF, and 1 mM Na3VO4). 20 µg of cell 
lysate was subjected to SDS-PAGE and transferred onto an Immobilon polyvinylidene difluoride membrane 
(Millipore). Protein detection was carried out using antibodies against phosphorylated STAT1 (BD Biosciences, 
CA, USA) and a monoclonal antibody against GAPDH (sc-32233, Santa Cruz, CA, USA).
Bleomycin-induced skin fibrosis mouse model. Skin fibrosis was induced in 6–8 week-old, 
pathogen-free WT or Htr7−/−100 female C57BL/6NJ (The Jackson Laboratory) by subcutaneous injections of 
100 μg of bleomycin (1 mg/ml, Mylan Pharmaceuticals, Barcelona, Spain) or 0.9% saline control into the shaved 
back skin every day for 4 weeks as previously described61,101. Skin was harvested and frozen for mRNA/protein 
studies or paraffin embedded for histological studies. Fibrosis was determined by Masson’s trichrome staining, 
and the presence of α-SMA+ or F4/80+ determined using anti-α Smooth Muscle Actin antibody (α-SMA; 1A4 
clone, Sigma-Aldrich, Spain) and anti-F4/80 antibody (BM8 clone; eBioscience, San Diego, CA, USA).
Statistical analysis. For comparison of means, and unless otherwise indicated, statistical significance of the 
generated data was evaluated using the Student t test. In all cases, p < 0.05 was considered as statistically significant.
Data Availability. All data generated or analysed during this study are included in this published article. 
Moreover, microarray data were deposited in the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) 
under accession GSE94608.
References
 1. Lesurtel, M., Soll, C., Graf, R. & Clavien, P. A. Role of serotonin in the hepato-gastroIntestinal tract: an old molecule for new 
perspectives. Cell Mol Life Sci 65, 940–952 (2008).
 2. Amireault, P., Sibon, D. & Cote, F. Life without peripheral serotonin: insights from tryptophan hydroxylase 1 knockout mice reveal the 
existence of paracrine/autocrine serotonergic networks. ACS Chem Neurosci 4, 64–71, https://doi.org/10.1021/cn300154j (2013).
 3. Berger, M., Gray, J. A. & Roth, B. L. The expanded biology of serotonin. Annu Rev Med 60, 355–366, https://doi.org/10.1146/
annurev.med.60.042307.110802 (2009).
 4. Kaumann, A. J. & Levy, F. O. 5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacology & therapeutics 
111, 674–706 (2006).
 5. Spiller, R. Serotonin and GI clinical disorders. Neuropharmacology 55, 1072–1080, https://doi.org/10.1016/j.
neuropharm.2008.07.016 (2008).
 6. Yano, J. M. et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 161, 264–276, https://doi.
org/10.1016/j.cell.2015.02.047 (2015).
 7. Nemecek, G. M., Coughlin, S. R., Handley, D. A. & Moskowitz, M. A. Stimulation of aortic smooth muscle cell mitogenesis by 
serotonin. Proceedings of the National Academy of Sciences of the United States of America 83, 674–678 (1986).
 8. Lesurtel, M. et al. Platelet-derived serotonin mediates liver regeneration. Science 312, 104–107 (2006).
 9. Pakala, R., Willerson, J. T. & Benedict, C. R. Mitogenic effect of serotonin on vascular endothelial cells. Circulation 90, 1919–1926 
(1994).
 10. Barnes, N. M. & Sharp, T. A review of central 5-HT receptors and their function. Neuropharmacology 38, 1083–1152 (1999).
 11. Ahern, G. P. 5-HT and the immune system. Curr Opin Pharmacol 11, 29–33.
 12. Leon-Ponte, M., Ahern, G. P. & O’Connell, P. J. Serotonin provides an accessory signal to enhance T-cell activation by signaling 
through the 5-HT7 receptor. Blood 109, 3139–3146 (2007).
 13. Arzt, E., Costas, M., Finkielman, S. & Nahmod, V. E. Serotonin inhibition of tumor necrosis factor-alpha synthesis by human 
monocytes. Life sciences 48, 2557–2562 (1991).
 14. Cloez-Tayarani, I., Petit-Bertron, A. F., Venters, H. D. & Cavaillon, J. M. Differential effect of serotonin on cytokine production in 
lipopolysaccharide-stimulated human peripheral blood mononuclear cells: involvement of 5-hydroxytryptamine2A receptors. 
International immunology 15, 233–240 (2003).
 15. Durk, T. et al. 5-Hydroxytryptamine modulates cytokine and chemokine production in LPS-primed human monocytes via 
stimulation of different 5-HTR subtypes. International immunology 17, 599–606 (2005).
 16. Menard, G., Turmel, V. & Bissonnette, E. Y. Serotonin modulates the cytokine network in the lung: involvement of prostaglandin 
E2. Clinical and experimental immunology 150, 340–348 (2007).
 17. Launay, J. M. et al. Serotonin 5-HT2B receptors are required for bone-marrow contribution to pulmonary arterial hypertension. 
Blood 119, 1772–1780, https://doi.org/10.1182/blood-2011-06-358374 (2012).
 18. Morita, T. et al. HTR7 Mediates Serotonergic Acute and Chronic Itch. Neuron 87, 124–138, https://doi.org/10.1016/j.
neuron.2015.05.044 (2015).
 19. Dees, C. et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. The Journal of experimental medicine 208, 
961–972, https://doi.org/10.1084/jem.20101629 (2011).
 20. Kim, J. J. & Khan, W. I. 5-HT7 receptor signaling: improved therapeutic strategy in gut disorders. Front Behav Neurosci 8, 396, 
https://doi.org/10.3389/fnbeh.2014.00396 (2014).
 21. Levin, A. D. & van den Brink, G. R. Selective inhibition of mucosal serotonin as treatment for IBD? Gut 63, 866–867, https://doi.
org/10.1136/gutjnl-2013-305283 (2014).
 22. Kim, J. J. et al. Targeted inhibition of serotonin type 7 (5-HT7) receptor function modulates immune responses and reduces the 
severity of intestinal inflammation. J Immunol 190, 4795–4804, https://doi.org/10.4049/jimmunol.1201887 (2013).
www.nature.com/scientificreports/
13SCIentIfIC RepoRtS | 7: 14761  | DOI:10.1038/s41598-017-15348-y
 23. Guseva, D. et al. Serotonin 5-HT7 receptor is critically involved in acute and chronic inflammation of the gastrointestinal tract. 
Inflamm Bowel Dis 20, 1516–1529, https://doi.org/10.1097/MIB.0000000000000150 (2014).
 24. Ghia, J. E. et al. Serotonin has a key role in pathogenesis of experimental colitis. Gastroenterology 137, 1649–1660, https://doi.
org/10.1053/j.gastro.2009.08.041 (2009).
 25. Li, N. et al. Serotonin activates dendritic cell function in the context of gut inflammation. The American journal of pathology 178, 
662–671, https://doi.org/10.1016/j.ajpath.2010.10.028 (2011).
 26. Nocito, A. et al. Serotonin regulates macrophage-mediated angiogenesis in a mouse model of colon cancer allografts. Cancer 
research 68, 5152–5158 (2008).
 27. Svejda, B. et al. Serotonin and the 5-HT7 receptor: the link between hepatocytes, IGF-1 and small intestinal neuroendocrine 
tumors. Cancer Sci 104, 844–855, https://doi.org/10.1111/cas.12174 (2013).
 28. Chabbi-Achengli, Y. et al. Serotonin Is Involved in Autoimmune Arthritis through Th17 Immunity and Bone Resorption. The 
American journal of pathology 186, 927–937, https://doi.org/10.1016/j.ajpath.2015.11.018 (2016).
 29. Shajib, M. S. & Khan, W. I. The role of serotonin and its receptors in activation of immune responses and inflammation. Acta 
Physiol (Oxf) 213, 561–574, https://doi.org/10.1111/apha.12430 (2015).
 30. Nazimek, K. et al. The role of macrophages in anti-inflammatory activity of antidepressant drugs. Immunobiology, https://doi.
org/10.1016/j.imbio.2016.07.001 (2016).
 31. Su, H. C. et al. Glycogen synthase kinase-3beta regulates anti-inflammatory property of fluoxetine. Int Immunopharmacol 14, 
150–156, https://doi.org/10.1016/j.intimp.2012.06.015 (2012).
 32. Tsuchida, Y. et al. Neuronal stimulation with 5-hydroxytryptamine 4 receptor induces anti-inflammatory actions via alpha7nACh 
receptors on muscularis macrophages associated with postoperative ileus. Gut 60, 638–647, https://doi.org/10.1136/
gut.2010.227546 (2011).
 33. Maehara, T. et al. Therapeutic action of 5-HT3 receptor antagonists targeting peritoneal macrophages in post-operative ileus. 
British journal of pharmacology 172, 1136–1147, https://doi.org/10.1111/bph.13006 (2015).
 34. Jantsch, J., Binger, K. J., Muller, D. N. & Titze, J. Macrophages in homeostatic immune function. Frontiers in physiology 5, 146, 
https://doi.org/10.3389/fphys.2014.00146 (2014).
 35. Sica, A. & Mantovani, A. Macrophage plasticity and polarization: in vivo veritas. The Journal of clinical investigation 122, 787–795, 
https://doi.org/10.1172/JCI59643 (2012).
 36. Martinez, F. O., Sica, A., Mantovani, A. & Locati, M. Macrophage activation and polarization. Front Biosci 13, 453–461 (2008).
 37. Schultze, J. L. Reprogramming of macrophages–new opportunities for therapeutic targeting. Current opinion in pharmacology 26, 
10–15, https://doi.org/10.1016/j.coph.2015.09.007 (2016).
 38. Schultze, J. L., Freeman, T., Hume, D. A. & Latz, E. A transcriptional perspective on human macrophage biology. Seminars in 
immunology 27, 44–50, https://doi.org/10.1016/j.smim.2015.02.001 (2015).
 39. Kalkman, H. O. & Feuerbach, D. Antidepressant therapies inhibit inflammation and microglial M1-polarization. Pharmacology & 
therapeutics 163, 82–93, https://doi.org/10.1016/j.pharmthera.2016.04.001 (2016).
 40. Verreck, F. A. et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert 
immunity to (myco)bacteria. Proceedings of the National Academy of Sciences of the United States of America 101, 4560–4565, 
https://doi.org/10.1073/pnas.0400983101 (2004).
 41. Li, G., Kim, Y. J. & Broxmeyer, H. E. Macrophage colony-stimulating factor drives cord blood monocyte differentiation into IL-
10(high)IL-12absent dendritic cells with tolerogenic potential. J Immunol 174, 4706–4717 (2005).
 42. Akagawa, K. S. Functional heterogeneity of colony-stimulating factor-induced human monocyte-derived macrophages. Int J 
Hematol 76, 27–34 (2002).
 43. Hamilton, J. A. Colony-stimulating factors in inflammation and autoimmunity. Nature reviews. Immunology 8, 533–544 (2008).
 44. de las Casas-Engel, M. et al. Serotonin skews human macrophage polarization through HTR2B and HTR7. Journal of immunology 
190, 2301–2310, https://doi.org/10.4049/jimmunol.1201133 (2013).
 45. Roth, B. L. Drugs and valvular heart disease. The New England journal of medicine 356, 6–9, https://doi.org/10.1056/NEJMp068265 
(2007).
 46. Schade, R., Andersohn, F., Suissa, S., Haverkamp, W. & Garbe, E. Dopamine agonists and the risk of cardiac-valve regurgitation. 
The New England journal of medicine 356, 29–38, https://doi.org/10.1056/NEJMoa062222 (2007).
 47. Cuevas, V. D. et al. MAFB Determines Human Macrophage Anti-Inflammatory Polarization: Relevance for the Pathogenic 
Mechanisms Operating in Multicentric Carpotarsal Osteolysis. J Immunol, https://doi.org/10.4049/jimmunol.1601667 (2017).
 48. Gonzalez-Dominguez, E. et al. Atypical Activin A and IL-10 Production Impairs Human CD16+Monocyte Differentiation into 
Anti-Inflammatory Macrophages. J Immunol 196, 1327–1337, https://doi.org/10.4049/jimmunol.1501177 (2016).
 49. Sierra-Filardi, E. et al. Activin A skews macrophage polarization by promoting a proinflammatory phenotype and inhibiting the 
acquisition of anti-inflammatory macrophage markers. Blood 117, 5092–5101 (2011).
 50. Lovell, P. J. et al. A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-
sulfonyl) phen ol (SB-269970). J Med Chem 43, 342–345 (2000).
 51. Pouzet, B. SB-258741: a 5-HT7 receptor antagonist of potential clinical interest. CNS Drug Rev 8, 90–100 (2002).
 52. Forbes, I. T., Jones, G. E., Murphy, O. E., Holland, V. & Baxter, G. S. N-(1-methyl-5-indolyl)-N’-(3-methyl-5-isothiazolyl)urea: a 
novel, high-affinity 5-HT2B receptor antagonist. J Med Chem 38, 855–857 (1995).
 53. Raymond, J. R. et al. Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacology & therapeutics 92, 
179–212 (2001).
 54. Wynn, T. A. & Vannella, K. M. Macrophages in Tissue Repair, Regeneration, and Fibrosis. Immunity 44, 450–462, https://doi.
org/10.1016/j.immuni.2016.02.015 (2016).
 55. Munoz-Canoves, P. & Serrano, A. L. Macrophages decide between regeneration and fibrosis in muscle. Trends Endocrinol Metab 
26, 449–450, https://doi.org/10.1016/j.tem.2015.07.005 (2015).
 56. Christmann, R. B. et al. Association of Interferon- and transforming growth factor beta-regulated genes and macrophage activation 
with systemic sclerosis-related progressive lung fibrosis. Arthritis Rheumatol 66, 714–725, https://doi.org/10.1002/art.38288 (2014).
 57. Stifano, G. et al. Chronic Toll-like receptor 4 stimulation in skin induces inflammation, macrophage activation, transforming 
growth factor beta signature gene expression, and fibrosis. Arthritis Res Ther 16, R136, https://doi.org/10.1186/ar4598 (2014).
 58. Murray, L. A. et al. TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P. The international 
journal of biochemistry & cell biology 43, 154–162, https://doi.org/10.1016/j.biocel.2010.10.013 (2011).
 59. Murray, L. A. et al. Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on 
macrophages. PloS one 5, e9683, https://doi.org/10.1371/journal.pone.0009683 (2010).
 60. Lemos, D. R. et al. Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro/
adipogenic progenitors. Nature medicine 21, 786–794, https://doi.org/10.1038/nm.3869 (2015).
 61. Yamamoto, T. Animal model of systemic sclerosis. J Dermatol 37, 26–41, https://doi.org/10.1111/j.1346-8138.2009.00764.x (2010).
 62. Ruffell, D. et al. A CREB-C/EBPbeta cascade induces M2 macrophage-specific gene expression and promotes muscle injury repair. 
Proceedings of the National Academy of Sciences of the United States of America 106, 17475–17480 (2009).
 63. Lumeng, C. N., Bodzin, J. L. & Saltiel, A. R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. The 
Journal of clinical investigation 117, 175–184 (2007).
www.nature.com/scientificreports/
1 4SCIentIfIC RepoRtS | 7: 14761  | DOI:10.1038/s41598-017-15348-y
 64. Ruffell, B. & Coussens, L. M. Macrophages and therapeutic resistance in cancer. Cancer Cell 27, 462–472, https://doi.org/10.1016/j.
ccell.2015.02.015 (2015).
 65. Gordon, S. & Martinez, F. O. Alternative activation of macrophages: mechanism and functions. Immunity 32, 593–604 (2010).
 66. Mantovani, A., Biswas, S. K., Galdiero, M. R., Sica, A. & Locati, M. Macrophage plasticity and polarization in tissue repair and 
remodelling. The Journal of pathology 229, 176–185, https://doi.org/10.1002/path.4133 (2013).
 67. Jaffre, F. et al. Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of 
interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha cytokine production by ventricular fibroblasts. Circulation 110, 
969–974 (2004).
 68. Nebigil, C. G. et al. Overexpression of the serotonin 5-HT2B receptor in heart leads to abnormal mitochondrial function and 
cardiac hypertrophy. Circulation 107, 3223–3229 (2003).
 69. Elangbam, C. S. Drug-induced valvulopathy: an update. Toxicol Pathol 38, 837–848, https://doi.org/10.1177/0192623310378027 
(2010).
 70. Puig-Kroger, A. et al. Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-
inflammatory/regulatory macrophages. Cancer research 69, 9395–9403 (2009).
 71. Li, H., Nagai, T., Hasui, K. & Matsuyama, T. Depletion of folate receptor beta-expressing macrophages alleviates bleomycin-
induced experimental skin fibrosis. Mod Rheumatol 24, 816–822, https://doi.org/10.3109/14397595.2013.879415 (2014).
 72. Holst, K. et al. The serotonin receptor 5-HT(7)R regulates the morphology and migratory properties of dendritic cells. Journal of 
cell science 128, 2866–2880, https://doi.org/10.1242/jcs.167999 (2015).
 73. Polat, B. et al. Liver 5-HT7 receptors: A novel regulator target of fibrosis and inflammation-induced chronic liver injury in vivo and 
in vitro. Int Immunopharmacol 43, 227–235, https://doi.org/10.1016/j.intimp.2016.12.023 (2017).
 74. Gellynck, E. et al. The serotonin 5-HT7 receptors: two decades of research. Exp Brain Res 230, 555–568, https://doi.org/10.1007/
s00221-013-3694-y (2013).
 75. Bard, J. A. et al. Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. The Journal of 
biological chemistry 268, 23422–23426 (1993).
 76. Tuladhar, B. R., Ge, L. & Naylor, R. J. 5-HT7 receptors mediate the inhibitory effect of 5-HT on peristalsis in the isolated guinea-pig 
ileum. British journal of pharmacology 138, 1210–1214, https://doi.org/10.1038/sj.bjp.0705184 (2003).
 77. Idzko, M. et al. The serotoninergic receptors of human dendritic cells: identification and coupling to cytokine release. Journal of 
immunology 172, 6011–6019 (2004).
 78. Soga, F., Katoh, N., Inoue, T. & Kishimoto, S. Serotonin activates human monocytes and prevents apoptosis. The Journal of 
investigative dermatology 127, 1947–1955, https://doi.org/10.1038/sj.jid.5700824 (2007).
 79. Norum, J. H., Hart, K. & Levy, F. O. Ras-dependent ERK activation by the human G(s)-coupled serotonin receptors 5-HT4(b) and 
5-HT7(a). The Journal of biological chemistry 278, 3098–3104, https://doi.org/10.1074/jbc.M206237200 (2003).
 80. Johnson-Farley, N. N., Kertesy, S. B., Dubyak, G. R. & Cowen, D. S. Enhanced activation of Akt and extracellular-regulated kinase 
pathways by simultaneous occupancy of Gq-coupled 5-HT2A receptors and Gs-coupled 5-HT7A receptors in PC12 cells. J 
Neurochem 92, 72–82, https://doi.org/10.1111/j.1471-4159.2004.02832.x (2005).
 81. Lieb, K. et al. Serotonin via 5-HT7 receptors activates p38 mitogen-activated protein kinase and protein kinase C epsilon resulting 
in interleukin-6 synthesis in human U373 MG astrocytoma cells.  J Neurochem  93 ,  549–559, https://doi.
org/10.1111/j.1471-4159.2005.03079.x (2005).
 82. Kvachnina, E. et al. 5-HT7 receptor is coupled to G alpha subunits of heterotrimeric G12-protein to regulate gene transcription and 
neuronal morphology. J Neurosci 25, 7821–7830, https://doi.org/10.1523/JNEUROSCI.1790-05.2005 (2005).
 83. Renner, U. et al. Heterodimerization of serotonin receptors 5-HT1A and 5-HT7 differentially regulates receptor signalling and 
trafficking. Journal of cell science 125, 2486–2499, https://doi.org/10.1242/jcs.101337 (2012).
 84. Guseva, D., Wirth, A. & Ponimaskin, E. Cellular mechanisms of the 5-HT7 receptor-mediated signaling. Front Behav Neurosci 8, 
306, https://doi.org/10.3389/fnbeh.2014.00306 (2014).
 85. Shirshev, S. V. Role of Epac proteins in mechanisms of cAMP-dependent immunoregulation. Biochemistry (Mosc) 76, 981–998, 
https://doi.org/10.1134/S000629791109001X (2011).
 86. Peters-Golden, M. Putting on the brakes: cyclic AMP as a multipronged controller of macrophage function. Sci Signal 2, pe37, 
https://doi.org/10.1126/scisignal.275pe37 (2009).
 87. Lieder, H. R., Baars, T., Kahlert, P. & Kleinbongard, P. Aspirate from human stented saphenous vein grafts induces epicardial 
coronary vasoconstriction and impairs perfusion and left ventricular function in rat bioassay hearts with pharmacologically 
induced endothelial dysfunction. Physiol Rep 4, https://doi.org/10.14814/phy2.12874 (2016).
 88. Chojnacki, C. et al. Serum and ascitic fluid serotonin levels and 5-hydroxyindoleacetic acid urine excretion in the liver of cirrhotic 
patients with encephalopathy. Adv Med Sci 58, 251–256, https://doi.org/10.2478/ams-2013-0010 (2013).
 89. Abid, S. et al. Inhibition of gut- and lung-derived serotonin attenuates pulmonary hypertension in mice. American journal of 
physiology 303, L500–508, https://doi.org/10.1152/ajplung.00049.2012 (2012).
 90. Comai, S. et al. Serum levels of tryptophan, 5-hydroxytryptophan and serotonin in patients affected with different forms of 
amenorrhea. Int J Tryptophan Res 3, 69–75 (2010).
 91. Onaitis, M. W. et al. Gastrointestinal carcinoids: characterization by site of origin and hormone production. Ann Surg 232, 549–556 
(2000).
 92. Bunin, M. A. & Wightman, R. M. Quantitative evaluation of 5-hydroxytryptamine (serotonin) neuronal release and uptake: an 
investigation of extrasynaptic transmission. J Neurosci 18, 4854–4860 (1998).
 93. Duerschmied, D. et al. Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice. Blood 121, 
1008–1015, https://doi.org/10.1182/blood-2012-06-437392 (2013).
 94. Fleetwood, A. J., Dinh, H., Cook, A. D., Hertzog, P. J. & Hamilton, J. A. GM-CSF- and M-CSF-dependent macrophage phenotypes 
display differential dependence on type I interferon signaling. Journal of leukocyte biology 86, 411–421 (2009).
 95. Fleetwood, A. J., Lawrence, T., Hamilton, J. A. & Cook, A. D. Granulocyte-macrophage colony-stimulating factor (CSF) and 
macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: 
implications for CSF blockade in inflammation. Journal of immunology 178, 5245–5252 (2007).
 96. Hochberg, Y. & Benjamini, Y. More powerful procedures for multiple significance testing. Stat Med 9, 811–818 (1990).
 97. Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic acids research 44, 
W90–W97, https://doi.org/10.1093/nar/gkw377 (2016).
 98. Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14, 128, 
https://doi.org/10.1186/1471-2105-14-128 (2013).
 99. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression 
profiles. Proceedings of the National Academy of Sciences of the United States of America 102, 15545–15550, https://doi.org/10.1073/
pnas.0506580102 (2005).
 100. Hedlund, P. B. et al. No hypothermic response to serotonin in 5-HT7 receptor knockout mice. Proceedings of the National Academy 
of Sciences of the United States of America 100, 1375–1380, https://doi.org/10.1073/pnas.0337340100 (2003).
 101. Usategui, A., Criado, G., Del Rey, M. J., Fare, R. & Pablos, J. L. Topical vitamin D analogue calcipotriol reduces skin fibrosis in 
experimental scleroderma. Arch Dermatol Res 306, 757–761, https://doi.org/10.1007/s00403-014-1466-6 (2014).
www.nature.com/scientificreports/
1 5SCIentIfIC RepoRtS | 7: 14761  | DOI:10.1038/s41598-017-15348-y
Acknowledgements
This work was supported by grants from Ministerio de Economía y Competitividad (SAF2011-23801 and 
SAF2014-52423-R to MAV and ALC, and PI I12/439 to JLP), “Programa de Actividades de I + D” from the 
Comunidad de Madrid/FEDER (RAPHYME S2010/BMD-2350 to JLP and ALC), and RIER (Red de Investigación 
en Inflamación y Enfermedades Reumáticas, RD12/09 to ALC and JLP) from the Instituto de Salud Carlos III, 
Ministerio de Economía y Competitividad, Spain (co-financed by FEDER, European Union). MCE was supported 
by an FPI predoctoral fellowship (BES-2009-021465) from Ministerio de Economía e Innovación.
Author Contributions
A.D.S., M.C.E., M.S.F., A.U., C.N. and V.D.C. performed research; A.D.S., M.A.V., J.L.P. and A.L.C. designed the 
research; A.D.S. analyzed data and prepared figures; A.L.C. wrote the paper.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-15348-y.
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
